(2026). The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: Results of the phase Ib/II BladderGATE clinical trial. The Oncologist.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"The Combination of Atezolizumab and BCG in High-risk Non-muscle Invasive Bladder Cancer: Results of the Phase Ib/II BladderGATE Clinical Trial."
The Oncologist 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"The Combination of Atezolizumab and BCG in High-risk Non-muscle Invasive Bladder Cancer: Results of the Phase Ib/II BladderGATE Clinical Trial."
The Oncologist, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.